BioArctic AB
BIOA-B.ST
Stockholm Stock Exchange322.60
SEK
- -
- -
BioArctic AB
BIOA-B.ST
(Stockholm Stock Exchange)
Recent
price
322.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BioArctic AB (publ) is a research-focused biopharmaceutical firm dedicated to the advancement of biological treatments for individuals afflicted with central nervous system disorders in Sweden and globally. The company's innovative pipeline emphasizes developing disease-modifying therapies for significant unmet medical needs in neurodegenerative conditions, notably Alzheimer's and Parkinson's disease. A cornerstone of its portfolio is Lecanemab (Leqembi®), a humanized monoclonal antibody designed to target and eliminate soluble amyloid-beta protofibrils, now approved for early Alzheimer's disease. This groundbreaking therapy was developed in collaboration with Eisai, who holds global development and commercialization responsibilities, with BioArctic retaining rights for co-commercialization within the Nordic region and receiving tiered royalties and milestone payments from global sales. Further advancing Alzheimer's research, a Lecanemab back-up program is currently in preclinical stages. In its pursuit of Parkinson's disease treatments, BioArctic initially developed ABBV-0805, a monoclonal antibody targeting alpha-synuclein aggregates. While AbbVie had partnered on this program and initiated Phase 1 trials, the collaboration was ultimately terminated in 2022, and BioArctic is now evaluating further development options for the asset. The company also had a program for spinal cord injuries, SC0806, involving a biodegradable device. However, clinical development for this candidate was terminated in 2019 following an interim analysis of Phase 1/2 data that indicated a lack of efficacy. BioArctic’s pipeline extends to other projects, including a PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program for Alzheimer's disease, featuring candidates BAN1503 and BrainTransporter-enabled BAN2803, which are partnered with Bristol Myers Squibb in a significant global licensing agreement. The firm additionally conducts research into novel antibodies for other neurodegenerative disorders such as ALS and enzyme deficiency diseases, alongside developing crucial imaging and biochemical biomarkers for Alzheimer's and Parkinson's. A key proprietary innovation is the BrainTransporter™ platform, a technology that significantly enhances the delivery of therapeutic antibodies and other biologics across the blood-brain barrier by leveraging the transferrin receptor, showing up to a 70-fold increase in brain penetration in preclinical models. This platform is central to several internal projects and has attracted new collaborations, including an option, collaboration, and license agreement with Novartis in August 2025 for an undisclosed neurodegeneration target, and a research evaluation agreement with Eisai in April 2024 for BAN2802. BioArctic is also exploring new technologies through an evaluation agreement with Beactica Therapeutics for its Eclipsor™ platform in CNS disorders. Established in 2000 and headquartered in Stockholm, Sweden, BioArctic AB (publ) continues its mission to address profound medical needs through scientific innovation. The company’s revenue model is largely driven by strategic partnerships, including upfront payments, milestone achievements, and royalties from global product sales.